CoChat
Sign Up
Cited by 194

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Matrix metalloproteinase collagenolysis in health and disease

Amar, Sabrina, Smith, Lyndsay, Fields, Gregg B.·2017·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
DOI 10.1016/j.bbamcr.2017.04.015PMC PMC5605394
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbamcr.2017.04.015

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MT1-MMP is highly expressed in various types of cancer cells and promotes cancer metastasis and angiogenesis.

    “It is well documented that MT1-MMP is highly expressed in various types of cancer cells and promotes cancer metastasis and angiogenesis16,44,47–50.”

    From Membrane type 1 matrix metalloproteinase promotes LDL receptor shedding and accelerates the development of atherosclerosis (2021) · cites this paper as [44]

    Section 5, “The role of collagen catabolism in disease” (page unavailable), says MT1-MMP appears to play a significant role in tumor metastasis and that its collagenolysis has been correlated with metastasis in vivo. It does not establish that MT1-MMP is highly expressed across various cancer-cell types or that it promotes angiogenesis; its discussion of endothelial-cell migration does not establish the latter claim. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • MT1-MMP is highly expressed in various types of cancer cells and promotes cancer metastasis and angiogenesis.

    “MT1-MMP is highly expressed in various types of cancer cells and promotes cancer metastasis and angiogenesis [57,59].”

    From Post-translational regulation of the low-density lipoprotein receptor provides new targets for cholesterol regulation (2024) · cites this paper as [59]

    Section 5, “The role of collagen catabolism in disease” (page unavailable), says MT1-MMP appears to play a significant role in tumor metastasis and reports a correlation between its collagenolysis and metastasis in vivo. It does not say MT1-MMP is highly expressed across various cancer-cell types or that it promotes angiogenesis; its discussion of endothelial-cell migration does not establish the latter claim. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • MT1-MMP is highly expressed in multiple cancer cell types promoting metastasis and invasion.

    “Interestingly, MT1-MMP is also highly expressed in multiple cancer cell types promoting metastasis and invasion106,108, thus inhibiting MT1-MMP holds both promise as a therapeutic target to reduce the risk of cancer metastasis and lower plasma LDL cholesterol.”

    From Pathways and Molecular Mechanisms Governing LDL Receptor Regulation (2025) · cites this paper as [108]

    Section 5, “The role of collagen catabolism in disease” (page not provided), says MT1-MMP activity is critical for tumor-cell invasion through collagen and appears to play a significant role in metastasis. It does not establish that MT1-MMP is highly expressed in multiple cancer cell types; the expression passages found concern tuberculosis, not cancer. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 238

  1. Gross, 1962, Collagenolytic activity in amphibian tissues: a tissue culture assay, Proc. Natl. Acad. Sci. U. S. A., 48, 1014, 10.1073/pnas.48.6.1014 · DOI
  2. Whittaker, 1999, Design and therapeutic application of matrix metalloproteinase inhibitors, Chem. Rev., 99, 2735, 10.1021/cr9804543 · DOI
  3. Breuer, 2005, Recent non-hydroxamate matrix metalloproteinase inhibitors, Expert Opin. Ther. Pat., 15, 253, 10.1517/13543776.15.3.253 · DOI
  4. Mohan, 2016, Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine, Metalloproteinases Med., 3, 31, 10.2147/MNM.S65143 · DOI
  5. Fox, 2000, European roundup: no anticancer benefit in trials of marimastat, Gen. Eng. News, 20, 30
  6. Bloomston, 2002, Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials, Ann. Surg. Oncol., 9, 668, 10.1007/BF02574483 · DOI
  7. Li, 2009, Selective matrix metalloproteinase inhibitors for cancer, Curr. Med. Chem., 16, 3805, 10.2174/092986709789178037 · DOI
  8. Overall, 2006, Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy, Nat. Rev. Cancer, 6, 227, 10.1038/nrc1821 · DOI
  9. Martin, 2007, The other side of MMPs: protective roles in tumor progression, Cancer Metastasis Rev., 26, 717, 10.1007/s10555-007-9089-4 · DOI
  10. Decock, 2011, Matrix metalloproteinases: protective roles in cancer, J. Cell. Mol. Med., 15, 1254, 10.1111/j.1582-4934.2011.01302.x · DOI
  11. Dufour, 2013, Missing the target: matrix metalloproteinase antitargets in inflammation and cancer, Trends Pharmacol. Sci., 34, 233, 10.1016/j.tips.2013.02.004 · DOI
  12. Butler, 2007, Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry, Curr. Pharm. Des., 13, 263, 10.2174/138161207779313524 · DOI
  13. Cauwe, 2007, The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases, Crit. Rev. Biochem. Mol. Biol., 42, 113, 10.1080/10409230701340019 · DOI
  14. Butler, 2009, Updated biological roles for matrix metalloproteinases and new “intracellular” substrates revealed by degradomics, Biochemistry, 48, 10830, 10.1021/bi901656f · DOI
  15. Cauwe, 2010, Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases, Crit. Rev. Biochem. Mol. Biol., 45, 351, 10.3109/10409238.2010.501783 · DOI
  16. Rodríguez, 2010, Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics, Biochim. Biophys. Acta, 1803, 39, 10.1016/j.bbamcr.2009.09.015 · DOI
  17. Fortelny, 2014, Network analyses reveal pervasive functional regulation between proteases in the human protease web, PLoS Biol., 12, 10.1371/journal.pbio.1001869 · DOI
  18. Bertini, 2012, Structural basis for matrix metalloproteinase 1 catalyzed collagenolysis, J. Am. Chem. Soc., 134, 2100, 10.1021/ja208338j · DOI
  19. Cerofolini, 2013, Examination of matrix metalloproteinase-1 (MMP-1) in solution: a preference for the pre-collagenolysis state, J. Biol. Chem., 288, 30659, 10.1074/jbc.M113.477240 · DOI
  20. Zhao, 2015, Transient collagen triple helix binding to a key metalloproteinase in invasion and development, Structure, 23, 257, 10.1016/j.str.2014.11.021 · DOI
  21. Myllyharju, 2001, Collagen and collagen-related diseases, Ann. Med., 33, 7, 10.3109/07853890109002055 · DOI
  22. Hashimoto, 2002, CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV, EMBO J., 21, 1524, 10.1093/emboj/21.7.1524 · DOI
  23. Bella, 1994, Crystal and molecular structure of a collagen-like peptide at 1.9Å resolution, Science, 266, 75, 10.1126/science.7695699 · DOI
  24. Holmgren, 1998, Code for collagen's stability deciphered, Nature, 392, 666, 10.1038/33573 · DOI
  25. Saffarian, 2004, Interstitial collagenase is a Brownian rachet driven by proteolysis of collagen, Science, 306, 108, 10.1126/science.1099179 · DOI
  26. Cole, 1994, Collagen genes: mutations affecting collagen structure and expression, Prog. Nucleic Acid Res. Mol. Biol., 47, 29, 10.1016/S0079-6603(08)60249-4 · DOI
  27. Herr, 2009, Structural insights into the interactions between platelet receptors and fibrillar collagen, J. Biol. Chem., 284, 19781, 10.1074/jbc.R109.013219 · DOI
  28. Shoulders, 2009, Collagen structure and stability, Annu. Rev. Biochem., 78, 929, 10.1146/annurev.biochem.77.032207.120833 · DOI · Paper page
  29. Prockop, 1995, Collagens: molecular biology, diseases, and potentials for therapy, Annu. Rev. Biochem., 64, 403, 10.1146/annurev.bi.64.070195.002155 · DOI
  30. Heikkinen, 2000, Lysyl hydroxylase 3 is a multifunctional protein possessing collagen glucosyltransferase activity, J. Biol. Chem., 275, 36158, 10.1074/jbc.M006203200 · DOI
  31. Takaluoma, 2007, Lysyl hydroxylase 2 is a specific telopeptide hydroxylase, while all three isoenzymes hydroxylate collagenous sequences, Matrix Biol., 26, 396, 10.1016/j.matbio.2007.01.002 · DOI
  32. Schegg, 2009, Core glycosylation of collagen is initiated by two β(1-O)galactosyltransferases, Mol. Cell. Biol., 29, 943, 10.1128/MCB.02085-07 · DOI
  33. Bächinger, 1978, The role of cis-trans isomerization of peptide bonds in the coil <=> triple helix conversion of collagen, Eur. J. Biochem., 90, 605, 10.1111/j.1432-1033.1978.tb12641.x · DOI
  34. Bächinger, 1980, Folding mechanism of the triple helix in type-III collagen and type-III pN-collagen, Eur. J. Biochem., 106, 619, 10.1111/j.1432-1033.1980.tb04610.x · DOI
  35. Baum, 1999, Folding of peptide models of collagen and misfolding in disease, Curr. Opin. Struct. Biol., 9, 122, 10.1016/S0959-440X(99)80016-5 · DOI
  36. Persikov, 2002, Unstable molecules form stable tissues, Proc. Natl. Acad. Sci. U. S. A., 99, 1101, 10.1073/pnas.042707899 · DOI
  37. Makareeva, 2007, Procollagen triple helix assembly: an unconventional chaperone-assisted folding paradigm, PLoS One, 2, 10.1371/journal.pone.0001029 · DOI
  38. Ono, 2012, Direct in vitro and in vivo evidence for interaction between Hsp47 protein and collagen triple helix, J. Biol. Chem., 287, 6810, 10.1074/jbc.M111.280248 · DOI
  39. Widmer, 2012, Molecular basis for the action of the collagen-specific chaperone Hsp47/SERPINH1 and its structure-specific client recognition, Proc. Natl. Acad. Sci. U. S. A., 109, 13243, 10.1073/pnas.1208072109 · DOI
  40. Tortorella, 2009, A review of the ADAMTS family, pharmaceutical targets of the future, Curr. Pharm. Des., 15, 2359, 10.2174/138161209788682433 · DOI
  41. Li, 1996, The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein-1, Proc. Natl. Acad. Sci. U. S. A., 93, 5127, 10.1073/pnas.93.10.5127 · DOI
  42. Sieron, 2000, Structure and function of procollagen C-proteinase (mTolloid) domains determined by protease digestion, cicular dichroism, binding to procollagen type I, and computer modeling, Biochemistry, 39, 3231, 10.1021/bi992312o · DOI
  43. Kronenberg, 2010, Processing of procollagen III by meprins: new players in extracellular matrix assembly?, J. Invest. Dermatol., 130, 2727, 10.1038/jid.2010.202 · DOI
  44. Kadler, 1996, Collagen fibril formation, Biochem. J., 316, 1, 10.1042/bj3160001 · DOI
  45. Bruckner, 1981, Proteolytic enzymes as probes for the triple-helical conformation of procollagen, Anal. Biochem., 110, 360, 10.1016/0003-2697(81)90204-9 · DOI
  46. Welgus, 1985, Degradation of monomeric and fibrillar type III collagens by human skin collagenase, J. Biol. Chem., 260, 1052, 10.1016/S0021-9258(20)71207-X · DOI
  47. Minond, 2006, The roles of substrate thermal stability and P2 and P1′ subsite identity on matrix metalloproteinase triple-helical peptidase activity and collagen specificity, J. Biol. Chem., 281, 38302, 10.1074/jbc.M606004200 · DOI
  48. Williams, 2009, Matrix metalloproteinase-1 cleavage site recognition and binding in full-length human type III collagen, Matrix Biol., 28, 373, 10.1016/j.matbio.2009.04.009 · DOI
  49. Knäuper, 1996, Biochemical characterization of human collagenase-3, J. Biol. Chem., 271, 1544, 10.1074/jbc.271.3.1544 · DOI
  50. Birkedal-Hansen, 1985, Cleavage of bovine skin type III collagen by proteolytic enzymes, J. Biol. Chem., 260, 16411, 10.1016/S0021-9258(17)36252-X · DOI
  51. Welgus, 1981, Human skin fibroblast collagenase: assessment of activation energy and deuterium isotope effect with collagenous substrates, J. Biol. Chem., 256, 9516, 10.1016/S0021-9258(19)68793-4 · DOI
  52. Fields, 1991, A model for interstitial collagen catabolism by mammalian collagenases, J. Theor. Biol., 153, 585, 10.1016/S0022-5193(05)80157-2 · DOI
  53. Freije, 1994, Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas, J. Biol. Chem., 269, 16766, 10.1016/S0021-9258(19)89457-7 · DOI
  54. Mitchell, 1996, Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage, J. Clin. Invest., 97, 761, 10.1172/JCI118475 · DOI
  55. Stolow, 1996, Identification and characterization of a novel collagenase in Xenopus laevis: possible roles during frog development, Mol. Biol. Cell, 7, 1471, 10.1091/mbc.7.10.1471 · DOI
  56. Yang, 1998, Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts, J. Biol. Chem., 273, 17893, 10.1074/jbc.273.28.17893 · DOI
  57. Ala-aho, 2005, Collagenases in cancer, Biochimie, 87, 273, 10.1016/j.biochi.2004.12.009 · DOI
  58. Fields, 2013, Interstitial collagen catabolism, J. Biol. Chem., 288, 8785, 10.1074/jbc.R113.451211 · DOI · Paper page
  59. Hasty, 1987, The collagen substrate specificity of human neutrophil collagenase, J. Biol. Chem., 262, 10048, 10.1016/S0021-9258(18)61073-7 · DOI
  60. Aimes, 1995, Matrix metalloproteinase-2 is an interstitial collagenase, J. Biol. Chem., 270, 5872, 10.1074/jbc.270.11.5872 · DOI
  61. Konttinen, 1998, New collagenolytic enzymes/cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above, Matrix Biol., 17, 585, 10.1016/S0945-053X(98)90110-X · DOI
  62. Patterson, 2001, Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain, FEBS Lett., 503, 158, 10.1016/S0014-5793(01)02723-5 · DOI
  63. Seltzer, 1981, Purification and properties of a gelatin-specific neutral protease from human skin, J. Biol. Chem., 256, 4662, 10.1016/S0021-9258(19)69486-X · DOI
  64. Collier, 2011, Diffusion of MMPs on the surface of collagen fibrils: the mobile cell surface - collagen substratum interface, PLoS One, 6, 10.1371/journal.pone.0024029 · DOI
  65. Bigg, 2007, Activity of matrix metalloproteinase-9 against native collagen types I and III, FEBS J., 274, 1246, 10.1111/j.1742-4658.2007.05669.x · DOI
  66. Niyibizi, 1994, A 92kDa gelatinase (MMP-9) cleavage site in native type V collagen, Biochem. Biophys. Res. Commun., 202, 328, 10.1006/bbrc.1994.1931 · DOI
  67. O'Farrell, 1998, The fibronectin-like domain is required for the type V and XI collagenolytic activity of gelatinase B, Arch. Biochem. Biophys., 354, 24, 10.1006/abbi.1998.0662 · DOI
  68. O'Farrell, 2000, Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes, J. Biol. Chem., 275, 27964, 10.1074/jbc.M003936200 · DOI
  69. Hotary, 2000, Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3, J. Cell Biol., 149, 1309, 10.1083/jcb.149.6.1309 · DOI
  70. Ohuchi, 1997, Membrane type I matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules, J. Biol. Chem., 272, 2446, 10.1074/jbc.272.4.2446 · DOI · Paper page
  71. Lehti, 2002, Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase, J. Biol. Chem., 277, 8440, 10.1074/jbc.M109128200 · DOI
  72. Itoh, 2006, Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP, Mol. Biol. Cell, 17, 5390, 10.1091/mbc.e06-08-0740 · DOI
  73. Li, 2008, Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase, Mol. Biol. Cell, 19, 3221, 10.1091/mbc.e08-01-0016 · DOI
  74. Sabeh, 2009, Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion, J. Biol. Chem., 284, 23001, 10.1074/jbc.M109.002808 · DOI
  75. Cerofolini, 2016, Bilayer membrane modulation of membrane type 1 matrix metalloproteinase (MT1-MMP) structure and proteolytic activity, Nat. Sci. Rep., 6, 29511, 10.1038/srep29511 · DOI
  76. Tam, 2002, Collagen binding properties of the membrane type-1 matrix metalloproteinase (MT1-MMP) hemopexin C domain, J. Biol. Chem., 277, 39005, 10.1074/jbc.M206874200 · DOI
  77. Tochowicz, 2011, The dimer interface of the membrane type 1 matrix metalloproteinase hemopexin domain: crystal structure and biological functions, J. Biol. Chem., 286, 7587, 10.1074/jbc.M110.178434 · DOI
  78. Shimada, 1999, Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase, Eur. J. Biochem., 262, 907, 10.1046/j.1432-1327.1999.00459.x · DOI
  79. Jiang, 2003, Distinct roles of catalytic and pexin-like domains in membrane-type matrix metalloproteinase (MMP)-mediated pro-MMP-2 activation and collagenolysis, J. Biol. Chem., 278, 38765, 10.1074/jbc.M306618200 · DOI
  80. Tatti, 2011, Membrane-type-3 matrix metalloproteinase (MT3-MMP) functions as a matrix composition-dependent effector of melanoma cell invasion, PLoS One, 6, 10.1371/journal.pone.0028325 · DOI
  81. Shi, 2008, Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis, Dev. Biol., 313, 196, 10.1016/j.ydbio.2007.10.017 · DOI · Paper page
  82. Kang, 2001, Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils, J. Biol. Chem., 276, 21960, 10.1074/jbc.M007997200 · DOI
  83. Radichev, 2010, Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase, J. Biol. Chem., 285, 16076, 10.1074/jbc.M110.107094 · DOI
  84. Starr, 2012, Biochemical characterization and N-terminomics analysis of leukolysin, the membrane-type 6 matrix metalloprotease (MMP25), J. Biol. Chem., 287, 13382, 10.1074/jbc.M111.314179 · DOI
  85. Taddese, 2010, MMP-12 catalytic domain recognizes and cleaves at multiple sites in human skin collagen type I and type III, Biochim. Biophys. Acta, 1804, 731, 10.1016/j.bbapap.2009.11.014 · DOI
  86. Fu, 2001, Cloning, expression, purification, and characterization of rat MMP-12, Protein Expr. Purif., 21, 268, 10.1006/prep.2000.1376 · DOI
  87. Allan, 1991, Binding of latent and high Mr forms of stromelysin to collagen is mediated by the C-terminal domain, J. Cell Sci., 99, 789, 10.1242/jcs.99.4.789 · DOI
  88. Murphy, 1992, The role of the C-terminal domain in collagenase and stromelysin specificity, J. Biol. Chem., 267, 9612, 10.1016/S0021-9258(19)50134-X · DOI
  89. Chung, 2004, Collagenase unwinds triple helical collagen prior to peptide bond hydrolysis, EMBO J., 23, 3020, 10.1038/sj.emboj.7600318 · DOI
  90. Rosenblum, 2007, Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B, Structure, 15, 1227, 10.1016/j.str.2007.07.019 · DOI
  91. Bertini, 2008, Evidence of reciprocal reorientation of the catalytic and hemopexin-like domains of full-length MMP-12, J. Am. Chem. Soc., 130, 7011, 10.1021/ja710491y · DOI
  92. Bertini, 2009, Interdomain flexibility in full-length matrix metalloproteinase-1 (MMP-1), J. Biol. Chem., 284, 12821, 10.1074/jbc.M809627200 · DOI
  93. Rosenblum, 2010, Direct visualization of protease action on collagen triple helical structure, PLoS One, 5, 10.1371/journal.pone.0011043 · DOI
  94. Tsukada, 2002, Unexpected crucial role of residue 272 in substrate specificity of fibroblast collagenase, J. Biol. Chem., 277, 27378, 10.1074/jbc.M201367200 · DOI
  95. Fasciglione, 2012, The collagenolytic action of MMP-1 is regulated by the interaction between the catalytic domain and the hinge region, J. Biol. Inorg. Chem., 17, 663, 10.1007/s00775-012-0886-z · DOI
  96. Shuo, 2012, Detection of the heterogeneous O-glycosylation profile of MT1-MMP expressed in cancer cells by a simple MALDI-MS method, PLoS One, 7, 10.1371/journal.pone.0043751 · DOI
  97. Hirose, 1993, Structure-function relationship of human neutrophil collagenase: identification of regions responsible for substrate specificity and general proteinase activity, Proc. Natl. Acad. Sci. U. S. A., 90, 2569, 10.1073/pnas.90.7.2569 · DOI
  98. Chung, 2000, Identification of the RWTNNFREY(183–191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity, J. Biol. Chem., 275, 29610, 10.1074/jbc.M004039200 · DOI
  99. Brömme, 1996, Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts, J. Biol. Chem., 271, 2126, 10.1074/jbc.271.4.2126 · DOI
  100. Garnero, 1998, The collagenolytic acitivity of cathepsin K is unique among mammalian proteinases, J. Biol. Chem., 273, 32347, 10.1074/jbc.273.48.32347 · DOI
  101. Aguda, 2014, Structural basis of collagen fiber degradation by cathepsin K, Proc. Natl. Acad. Sci. U. S. A., 111, 17474, 10.1073/pnas.1414126111 · DOI
  102. Kafienah, 1998, Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix, Biochem. J., 331, 727, 10.1042/bj3310727 · DOI
  103. Sato, 1994, A matrix metalloproteinase expressed on the surface of invasive tumour cells, Nature, 370, 61, 10.1038/370061a0 · DOI
  104. Strongin, 1995, Mechanism of cell surface activation of 72-kDa type IV collagenase, J. Biol. Chem., 270, 5331, 10.1074/jbc.270.10.5331 · DOI
  105. Ellerbroek, 1999, Membrane associated matrix metalloproteinases in metastasis, BioEssays, 21, 940, 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.0.CO;2-J · DOI
  106. Kajita, 2001, Membrane-type 1 matrix metallproteinase cleaves CD44 and promotes cell migration, J. Cell Biol., 153, 893, 10.1083/jcb.153.5.893 · DOI
  107. Deryugina, 2002, Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase, J. Biol. Chem., 277, 9749, 10.1074/jbc.M110269200 · DOI
  108. Hwang, 2004, A proteomic approach to identify substrates of matrix metalloproteinase-14 in human plasma, Biochim. Biophys. Acta, 1702, 79, 10.1016/j.bbapap.2004.08.001 · DOI
  109. Tam, 2004, Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates, Proc. Natl. Acad. Sci. U. S. A., 101, 6917, 10.1073/pnas.0305862101 · DOI · Paper page
  110. Aoki, 2005, Cleavage of apolipoprotein E by membrane-type matrix metalloproteinase-1 abrogates suppression of cell proliferation, J. Biochem., 137, 95, 10.1093/jb/mvi009 · DOI
  111. Koshikawa, 2005, Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain, J. Biol. Chem., 280, 88, 10.1074/jbc.M411824200 · DOI
  112. Egawa, 2006, Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells, J. Biol. Chem., 281, 37576, 10.1074/jbc.M606993200 · DOI
  113. Takino, 2006, Membrane-type 1 matrix metalloproteinase modulates focal adhesion stability and cell migration, Exp. Cell Res., 312, 1381, 10.1016/j.yexcr.2006.01.008 · DOI
  114. Itoh, 2006, MT1-MMP: a key regulator of cell migration in tissue, IUBMB Life, 58, 589, 10.1080/15216540600962818 · DOI
  115. Butler, 2008, Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding, Mol. Cell. Biol., 28, 4896, 10.1128/MCB.01775-07 · DOI
  116. Strongin, 2010, Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy, Biochim. Biophys. Acta, 1803, 133, 10.1016/j.bbamcr.2009.04.009 · DOI
  117. Liu, 2010, The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases, J. Immunol., 184, 3346, 10.4049/jimmunol.0903789 · DOI
  118. Liao, 2010, Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro, Biochemistry, 49, 1127, 10.1021/bi901994d · DOI · Paper page
  119. Pahwa, 2014, Monitoring and inhibiting MT1-MMP during cancer initiation and progression, Cancer, 6, 416, 10.3390/cancers6010416 · DOI
  120. Thakur, 2016, The membrane tethered matrix metalloproteinase MT1-MMP at the forefront of melanoma cell invasion and metastasis, Pharmacol. Res., 111, 17, 10.1016/j.phrs.2016.05.019 · DOI
  121. Golubkov, 2007, Proteolysis-driven oncogenesis, Cell Cycle, 6, 147, 10.4161/cc.6.2.3706 · DOI
  122. Wali, 2014, Centrosomal BRCA2 is a target protein of membrane type-1 matrix metalloproteinase (MT1-MMP), Biochem. Biophys. Res. Commun., 443, 1148, 10.1016/j.bbrc.2013.12.103 · DOI
  123. Dzamba, 1993, Fibronectin binding site in type I collagen regulates fibronectin fibril formation, J. Cell Biol., 121, 1165, 10.1083/jcb.121.5.1165 · DOI
  124. Davis, 1992, Affinity of integrins for damaged extracellular matrix: alphavbeta3 binds to denatured collagen type I through RGD sites, Biochem. Biophys. Res. Commun., 182, 1025, 10.1016/0006-291X(92)91834-D · DOI
  125. Berman, 1993, Adhesion of mouse hepatocytes to type I collagen: role of supramolecular forms and effect of proteolytic degradation, Biochem. Biophys. Res. Commun., 194, 351, 10.1006/bbrc.1993.1827 · DOI
  126. Montgomery, 1994, Integrin alphavbeta3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen, Proc. Natl. Acad. Sci. U. S. A., 91, 8856, 10.1073/pnas.91.19.8856 · DOI
  127. Solomonov, 2016, Distinct biological events generated by ECM proteolysis by two homologous collagenases, Proc. Natl. Acad. Sci. U. S. A., 113, 10884, 10.1073/pnas.1519676113 · DOI
  128. Lee, 2006, A critical role for the membrane-type 1 matrix metalloproteinase in collagen phagocytosis, Mol. Biol. Cell, 17, 4812, 10.1091/mbc.e06-06-0486 · DOI
  129. Wagenaar-Miller, 2007, Complementary roles of intracellular and pericellular collagen degradation pathways in vivo, Mol. Cell. Biol., 27, 6309, 10.1128/MCB.00291-07 · DOI
  130. Madsen, 2007, Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation, J. Biol. Chem., 282, 27037, 10.1074/jbc.M701088200 · DOI
  131. Madsen, 2011, The non-phagocytic route of collagen uptake: a distinct degradation pathway, J. Biol. Chem., 286, 26996, 10.1074/jbc.M110.208033 · DOI
  132. Lee, 2007, Phagocytosis of collagen by fibroblasts and invasive cancer cells in mediated by MT1-MMP, Biochem. Soc. Trans., 35, 704, 10.1042/BST0350704 · DOI
  133. Holmbeck, 1999, MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover, Cell, 99, 81, 10.1016/S0092-8674(00)80064-1 · DOI · Paper page
  134. Page-McCaw, 2007, Matrix metalloproteinases and the regulation of tissue remodelling, Nat. Rev. Mol. Cell Biol., 8, 221, 10.1038/nrm2125 · DOI · Paper page
  135. Evans, 2012, Mutation of membrane type-1 metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome, Am. J. Hum. Genet., 91, 572, 10.1016/j.ajhg.2012.07.022 · DOI
  136. Stickens, 2004, Altered endochondral bone development in matrix metalloproteinase 13-deficient mice, Development, 131, 5883, 10.1242/dev.01461 · DOI
  137. Kennedy, 2003, Matrix metalloproteinase 13 (MMP13) mutation causes spondyloepimetaphyseal dysplasia (SEMD), Missouri variant, Endocr. Abstr., 5, OC40
  138. Sulko, 2005, Novel amino acid substitution in the Y-position of collagen type II causes spondyloepimetaphyseal dysplasia congenita, Am. J. Med. Genet. A, 137A, 292, 10.1002/ajmg.a.30881 · DOI
  139. Subramanian, 2016, Identification of an electrostatic ruler motif for sequence-specific binding of collagenase to collagen, J. Phys. Chem. B, 120, 8580, 10.1021/acs.jpcb.6b02573 · DOI
  140. Ito, 2005, Guilty by association: some collagen II mutants alter the formation of ECM as a result of atypical interaction with fibronectin, J. Mol. Biol., 352, 382, 10.1016/j.jmb.2005.07.019 · DOI
  141. Taylor, 2015, Matrix metalloproteinase 14 is required for fibrous tissue expansion, eLife, 4, 10.7554/eLife.09345 · DOI
  142. Wu, 1990, Generation of collagenase-resistant collagen by site-directed mutagenesis of murine pro α1(I) collagen gene, Proc. Natl. Acad. Sci. U. S. A., 87, 5888, 10.1073/pnas.87.15.5888 · DOI
  143. Hasty, 1993, Susceptibility of type I collagen containing mutated α1(I) chains to cleavage by human neutrophil collagenase, Matrix, 13, 181, 10.1016/S0934-8832(11)80001-6 · DOI
  144. Hotary, 2003, Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix, Cell, 114, 33, 10.1016/S0092-8674(03)00513-0 · DOI
  145. Liu, 1995, A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling, J. Cell Biol., 130, 227, 10.1083/jcb.130.1.227 · DOI
  146. Krane, 1996, Different collagenase gene products have different roles in degradation of type I collagen, J. Biol. Chem., 271, 28509, 10.1074/jbc.271.45.28509 · DOI
  147. Lemaitre, 1997, The recombinant catalytic domain of mouse collagenase-3 depolymerizes type I collagen by cleaving its aminotelopeptides, Biochem. Biophys. Res. Commun., 230, 202, 10.1006/bbrc.1996.5924 · DOI
  148. Leikina, 2002, Type I collagen is thermally unstable at body temperature, Proc. Natl. Acad. Sci. U. S. A., 99, 1314, 10.1073/pnas.032307099 · DOI
  149. Zhao, 2000, Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen, J. Clin. Invest., 106, 941, 10.1172/JCI10158 · DOI
  150. Montgomery, 1994, Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line, Cancer Res., 54, 5467
  151. Zhao, 1999, Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice, J. Clin. Invest., 103, 517, 10.1172/JCI5481 · DOI
  152. Issa, 2003, Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration, FASEB J., 17, 47, 10.1096/fj.02-0494fje · DOI
  153. Beare, 2003, Severely impaired wound healing in the collagenase-resistant mouse, J. Invest. Dermatol., 120, 153, 10.1046/j.1523-1747.2003.12019.x · DOI
  154. Pilcher, 1997, The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix, J. Cell Biol., 137, 1445, 10.1083/jcb.137.6.1445 · DOI
  155. Rohani, 2015, Matrix remodeling by MMPs during wound repair, Matrix Biol., 44-46, 113, 10.1016/j.matbio.2015.03.002 · DOI · Paper page
  156. Zigrino, 2016, Fibroblast-derived MMP-14 regulates collagen homeostasis in adult skin, J. Invest. Dermatol., 136, 1575, 10.1016/j.jid.2016.03.036 · DOI
  157. Gelb, 1996, Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency, Science, 273, 1236, 10.1126/science.273.5279.1236 · DOI
  158. Everts, 1985, Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis, Calcif. Tissue Int., 37, 25, 10.1007/BF02557674 · DOI
  159. Everts, 2003, Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts, Calcif. Tissue Int., 73, 380, 10.1007/s00223-002-2092-4 · DOI
  160. Rünger, 2012, Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib, J. Am. Acad. Dermatol., 66, e89, 10.1016/j.jaad.2010.11.033 · DOI
  161. Liotta, 1992, Cancer cell invasion and metastasis, Sci. Am., 266, 54, 10.1038/scientificamerican0292-54 · DOI
  162. Birkedal-Hansen, 1993, Matrix metalloproteinases: a review, Crit. Rev. Oral Biol. Med., 4, 197, 10.1177/10454411930040020401 · DOI
  163. Chambers, 1997, Changing views of the role of matrix metalloproteinases in metastasis, J. Natl. Cancer Inst., 89, 1260, 10.1093/jnci/89.17.1260 · DOI
  164. Kleiner, 1999, Matrix metalloproteinases and metastasis, Cancer Chemother. Pharmacol., 43, S42, 10.1007/s002800051097 · DOI
  165. Nelson, 2000, Matrix metalloproteinases: biologic activity and clinical implications, J. Clin. Oncol., 18, 1135, 10.1200/JCO.2000.18.5.1135 · DOI
  166. Labrosse, 1976, A sensitive assay for collagenolytic activity using tritiated collagen, Anal. Biochem., 70, 218, 10.1016/S0378-5173(83)90103-5 · DOI
  167. Rowe, 2009, Navigating ECM barriers at the invasive front: the cancer cell-stroma interface, Annu. Rev. Cell Dev. Biol., 25, 567, 10.1146/annurev.cellbio.24.110707.175315 · DOI
  168. Gingras, 2010, Emerging concepts in the regulation of membrane-type 1 matrix metalloproteinase activity, Biochim. Biophys. Acta, 1803, 142, 10.1016/j.bbamcr.2009.04.011 · DOI
  169. Barbolina, 2008, Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis, Semin. Cell Dev. Biol., 19, 24, 10.1016/j.semcdb.2007.06.008 · DOI
  170. Szabova, 2007, MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease, Oncogene, 27, 3274, 10.1038/sj.onc.1210982 · DOI
  171. Zarrabi, 2011, Inhibition of matrix metalloproteinase-14 (MMP-14)-mediated cancer cell migration, J. Biol. Chem., 286, 33167, 10.1074/jbc.M111.256644 · DOI · Paper page
  172. Fisher, 2009, MT1-MMP- and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices, J. Cell Sci., 122, 4558, 10.1242/jcs.050724 · DOI
  173. Wolf, 2007, Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion, Nat. Cell Biol., 9, 893, 10.1038/ncb1616 · DOI
  174. Koike, 2002, MT1-MMP, but not secreted MMPs, influences the migration of human microvascular endothelial cells in 3-dimensional collagen gels, J. Cell. Biochem., 86, 748, 10.1002/jcb.10257 · DOI
  175. Zhang, 2006, Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo, BMC Cancer, 6, 52, 10.1186/1471-2407-6-52 · DOI
  176. Sabeh, 2004, Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP, J. Cell Biol., 167, 769, 10.1083/jcb.200408028 · DOI
  177. Sabeh, 2009, Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited, J. Cell Biol., 185, 11, 10.1083/jcb.200807195 · DOI
  178. Takino, 2010, MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix, Biochem. Biophys. Res. Commun., 396, 1042, 10.1016/j.bbrc.2010.05.059 · DOI
  179. Foley, 2012, Matrix metalloproteinase-1a promotes tumorigenesis and metastasis, J. Biol. Chem., 287, 24330, 10.1074/jbc.M112.356303 · DOI
  180. Makareeva, 2010, Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion, Cancer Res., 70, 4366, 10.1158/0008-5472.CAN-09-4057 · DOI
  181. Narayanan, 1984, Action of mammalian collagenases on type-I trimer collagen, Coll. Relat. Res., 4, 289, 10.1016/S0174-173X(84)80036-9 · DOI
  182. Ng, 2009, A stiff blow from the stroma: collagen crosslinking drives tumor progression, Cancer Cell, 16, 455, 10.1016/j.ccr.2009.11.013 · DOI
  183. Acerbi, 2015, Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration, Integr. Biol., 7, 1120, 10.1039/c5ib00040h · DOI
  184. Krantz, 2011, MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling, Mol. Cancer Res., 9, 1294, 10.1158/1541-7786.MCR-11-0023 · DOI
  185. Yu, 2000, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis, Genes Dev., 14, 163, 10.1101/gad.14.2.163 · DOI · Paper page
  186. Karsdal, 2002, Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis, J. Biol. Chem., 277, 44061, 10.1074/jbc.M207205200 · DOI
  187. Nguyen, 2016, MT1-MMP activation of TGF-β ® signaling enables intercellular activation of an epithelial-mesenchymal transition program in cancer, Curr. Cancer Drug Targets, 16, 618, 10.2174/1568009616666160216125634 · DOI
  188. Levental, 2009, Matrix crosslinking forces tumor progression by enhancing integrin signaling, Cell, 139, 891, 10.1016/j.cell.2009.10.027 · DOI · Paper page
  189. Caterson, 2000, Mechanisms involved in cartilage proteoglycan catabolism, Matrix Biol., 19, 333, 10.1016/S0945-053X(00)00078-0 · DOI
  190. Knudson, 2001, Cartilage proteoglycans, Semin. Cell Dev. Biol., 12, 69, 10.1006/scdb.2000.0243 · DOI
  191. Pratta, 2003, Aggrecan protects cartilage collagen from proteolytic cleavage, J. Biol. Chem., 278, 45539, 10.1074/jbc.M303737200 · DOI
  192. Porter, 2005, The ADAMTS metalloproteinases, Biochem. J., 386, 15, 10.1042/BJ20040424 · DOI · Paper page
  193. Neuhold, 2001, Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice, J. Clin. Invest., 107, 35, 10.1172/JCI10564 · DOI
  194. Smith, 2006, The role of collagenolytic matrix metalloproteinases in the loss of articular cartilage in osteoarthritis, Front. Biosci., 11, 3081, 10.2741/2034 · DOI
  195. Walling, 2003, Impairment of the collagenase-3 endocytotic receptor system in cells from patients with osteoarthritis, Osteoarthr. Cartil., 11, 854, 10.1016/S1063-4584(03)00170-5 · DOI
  196. Yamamoto, 2016, MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1, Matrix Biol., 56, 57, 10.1016/j.matbio.2016.03.007 · DOI
  197. Özler, 2016, Serum and knee synovial fluid matrix metalloproteinase-13 and tumor necrosis factor-alpha levels in patients with late-stage osteoarthritis, Acta Orthop. Traumatol. Turc., 50, 356, 10.1016/j.aott.2015.11.003 · DOI
  198. Baragi, 2009, A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models, Arthritis Rheum., 60, 2008, 10.1002/art.24629 · DOI
  199. Johnson, 2007, Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects, J. Biol. Chem., 282, 27781, 10.1074/jbc.M703286200 · DOI
  200. Novinec, 2013, Cathepsin K: a unique collagenolytic cysteine peptidase, Biol. Chem., 394, 1163, 10.1515/hsz-2013-0134 · DOI

200 of 238 shown

Cited by

Sorted by citations

Metadata

Authors
Amar, S., Smith, L., & Fields, G. B.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Publisher
Elsevier BV
Published
2017-11
Volume
1864
Issue
11
Pages
1940-1951
ISSN
0167-4889
DOI
10.1016/j.bbamcr.2017.04.015
PMC
PMC5605394
Cited by
194
References
2
Language
en
Licence
Funders
  • National Institutes of Health (CA98799, AR063795, MH078948, 268201000036C)
  • Multiple Sclerosis National Research Institute
  • Robert A. Welch Foundation
  • Lustgarten Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review